Abstract
Allergy is a significant component in many asthma patients. Omalizumab is a monoclonal anti-immunoglobulin E antibody for the treatment of allergic asthma. Clinical trials have shown that omalizumab treatment is associated with improved symptom control and reduced inhaled corticosteroid doses, resulting in fewer exacerbations and reduced utilization of resources. Omalizumab therapy may benefit patients who remain uncontrolled or who cannot tolerate standard therapy.
Key words: adult, asthma, immunoglobulin E, monoclonal antibody, prior authorization
More like this
- IgE-Blocking Therapy for Difficult-to-Treat Asthma: A Brief Review
- Managed Care Best Practices in the Treatment and Management of Asthma
- A New Approach for MS
- Insurance Gap Leaves Out Kids With Asthma
- Many Clinical Studies May Not Be Dependable
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.